Nat­era shares tum­ble af­ter short-sell­er al­leges de­cep­tive billing prac­tices — and pos­si­bly in­sur­ance fraud

Hin­den­burg Re­search — the short-sell­er firm that writes ex­posé re­ports every so of­ten, as in the case of Sor­ren­to Ther­a­peu­tics in 2020 — went af­ter ge­net­ics test­ing and DNA screen­ing com­pa­ny Nat­era in its newest re­port. And the re­sults are far from flat­ter­ing.

The in­vest­ment firm not­ed it wasn’t thrilled with the com­pa­ny from the get-go, and the ti­tle said it all with “Nat­era: Pi­o­neers In De­cep­tive Med­ical Billing.” The re­port went in­to de­tail about what it al­leged are shady billing prac­tices, in­clud­ing charg­ing both doc­tors and ex­pec­tant moth­ers the full amount for a test and hid­ing their ac­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER